TOP TEN perturbations for 39397_at (Homo sapiens)

Organism: Homo sapiens
Gene: 39397_at
Selected probe(set): 209120_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 39397_at (209120_at) across 6674 perturbations tested by GENEVESTIGATOR:

hepatocyte-like cell differentiation study 1 (20d; HNF4 depl) / hepatocyte-like cell differentiation study 1 (5d)

Relative Expression (log2-ratio):6.3914194
Number of Samples:3 / 3
Experimental hepatocyte-like cell differentiation study 1 (20d; HNF4 depl)
Hepatocyte-like cell differentiated from human pluripotent, embryonic stem cell line (ES, WA09) and transfected with shRNA targeting HNF4A. ES cells were grown in human ES cell media DMEM/F12 and differentiated to mature hepatocytes for 20 days. Moreover hESc was stable transfected with lentivirus expressing an shRNA that efficiently depletes HNF4A.
Control hepatocyte-like cell differentiation study 1 (5d)
Hepatocyte-like cell differentiated from human pluripotent, embryonic stem cell line (ES, WA09). ES cells were grown in human ES cell media DMEM/F12 and differentiated to definitive endoderm for 5 days.

hepatocyte-like cell differentiation study 1 (15d) / hepatocyte-like cell differentiation study 1 (5d)

Relative Expression (log2-ratio):5.5477533
Number of Samples:3 / 3
Experimental hepatocyte-like cell differentiation study 1 (15d)
Hepatocyte-like cells differentiated from human embryonic stem cells (ES, WA09), 15 days after the onset of differentiation. This stage is approximately corresponding to immature hepatocytes. Human H9 (WA09) ES cells were routinely cultured under low oxygen conditions (4% O2/5% CO2) in human ES cell media (DMEM/F12 medium supplemented with 20% knockout serum replacement, non essential amino acids, glutamine, penicillin/streptomycin and bFGF (4ng/ml) on Matrigel coated plates using MEF-conditioned human ES cell media. Differentiation was initiated by culture for 5 days with 100ng/ml Activin A in RPMI/B27 medium under ambient oxygen/5%CO2 followed by 5 days with 20ng/ml BMP4 /10ng/ml FGF-2 in RPMI/B27 under 4%O2/5%CO2, then 5 days with 20ng/ml HGF in RPMI/B27 supplement under 4%O2/5%CO2.
Control hepatocyte-like cell differentiation study 1 (5d)
Hepatocyte-like cell differentiated from human pluripotent, embryonic stem cell line (ES, WA09). ES cells were grown in human ES cell media DMEM/F12 and differentiated to definitive endoderm for 5 days.

Roberts syndrome study 1 / normal lymphoblastoid cell line sample

Relative Expression (log2-ratio):5.383909
Number of Samples:2 / 18
Experimental Roberts syndrome study 1
Lymphoblastoid cell line samples from probands with Roberts syndrome (RBS).
Control normal lymphoblastoid cell line sample
Lymphoblastoid cell line samples from healthy subjects.

stem cell differentiation study 59 (8d) / normal embryonic stem cell sample (WA09)

Relative Expression (log2-ratio):4.8645277
Number of Samples:4 / 4
Experimental stem cell differentiation study 59 (8d)
WA09 embryonic stem cell samples differentiated for 8 days. Further details are described in the paper.
Control normal embryonic stem cell sample (WA09)
Undifferentiated WA09 embryonic stem cell samples.

R547 study 1 (24h) / vehicle (DMSO) treated DU145 cell sample

Relative Expression (log2-ratio):-4.782853
Number of Samples:2 / 4
Experimental R547 study 1 (24h)
Human prostate carcinoma metastatic cell line DU145 treated with the CDK inhibitor R547 [4-amino-2-(1-methanesulfonylpiperidin-4-ylamino) pyrimidin-5-yl]-(2, 3-difluoro-6-methoxyphenyl)methanone (Hoffmann-La Roche compound) for 24 hours at a 3xIC90 concentration of 5.1 ╬╝mol/L. ATC code:---
Control vehicle (DMSO) treated DU145 cell sample
Human prostate carcinoma metastatic cell line DU145 treated with vehicle (DMSO) for 24 hours.

lung cancer study 1 (PDX; basaloid carcinoma; primary) / lung cancer study 1 (PDX; adenosquamous carcinoma; primary)

Relative Expression (log2-ratio):-4.624017
Number of Samples:3 / 4
Experimental lung cancer study 1 (PDX; basaloid carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary basaloid carcinoma of the lung (subcutaneously implanted).
Control lung cancer study 1 (PDX; adenosquamous carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenosquamous carcinoma of the lung (subcutaneously implanted).

echinomycin study 1 / deferoxamine study 5

Relative Expression (log2-ratio):-4.5186377
Number of Samples:3 / 3
Experimental echinomycin study 1
Echinomycin (100nM; 2h) treated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:---
Control deferoxamine study 5
Untreated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:

lung cancer study 1 (PDX; pseudosarcomatous carcinoma; primary) / lung cancer study 1 (PDX; basaloid carcinoma; primary)

Relative Expression (log2-ratio):4.363758
Number of Samples:4 / 3
Experimental lung cancer study 1 (PDX; pseudosarcomatous carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary pseudosarcomatous carcinoma of the lung (subcutaneously implanted).
Control lung cancer study 1 (PDX; basaloid carcinoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary basaloid carcinoma of the lung (subcutaneously implanted).

breast cancer study 24 / breast cancer study 22

Relative Expression (log2-ratio):4.308058
Number of Samples:10 / 10
Experimental breast cancer study 24
Freshly purified CD4+ tumor-infiltrating T cells derived from female primary invasive breast ductal carcinoma. For individual patient characteristics see detailed sample information. The initial tissue dissociation was performed mechanically, without enzymatic digestion.
Control breast cancer study 22
Freshly purified CD4+ T cells from peripheral blood of female donors with primary invasive breast ductal carcinoma. For individual patient characteristics see detailed sample information.

CNS cancer study 1 (PDX; glioma, malignant, NOS; primary) / CNS cancer study 1 (PDX; ependymoma, NOS; primary)

Relative Expression (log2-ratio):4.064827
Number of Samples:2 / 2
Experimental CNS cancer study 1 (PDX; glioma, malignant, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary glioma, malignant, NOS of the central nervous system (subcutaneously implanted).
Control CNS cancer study 1 (PDX; ependymoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary ependymoma, NOS of the central nervous system (subcutaneously implanted).